Medical Devices · Published Aug 2026
Urology Surgery Laser Market
The global urology surgery laser market is projected to expand from USD 6,313.0 million in 2025 to USD 12,418.6 million by 2035, reflecting a compound annual growth rate (CAGR) of 7.0%. This trajectory underscores the accelerating adoption of laser technologies in urological procedures, driven by precision, reduced recovery times, and minimally invasive outcomes. In Q1 2025, Medtronic launched its next-generation Holmium laser system, the VersaPulse PowerSuite, which integrates AI-driven energy modulation for lithotripsy procedures.
Concurrently, Boston Scientific expanded its GreenLight XPS platform to 450+ ambulatory surgical centers across the U.S., citing a 22% reduction in post-operative complications compared to traditional TURP methods. The market’s momentum is further fueled by rising prevalence of urolithiasis and benign prostatic hyperplasia (BPH), alongside growing demand for outpatient surgical solutions.
Market size
Growth trajectory through 2035
Urology Surgery Laser Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Q1 2025
- Medtronic launched the VersaPulse PowerSuite, an AI-integrated Holmium laser system, at the American Urological Association (AUA) Annual Meeting in April 2025.
-
2025 Q2 2025
- Boston Scientific received FDA clearance for its GreenLight XPS 180 system, expanding its BPH treatment portfolio. The system was deployed in 120+ U.S. hospitals within three months.
-
2025 Q3 2025
- Stryker’s NeoLaser 150, a 150W solid-state laser, received CE mark approval for European markets, enabling tumor ablation procedures with reduced collateral damage.
-
2025 Q4 2025
- Baxter introduced the LaserLite Pro, a portable Thulium laser system, targeting rural clinics in sub-Saharan Africa. The system weighs under 5 kg and is priced at USD 120,000.
Emerging opportunities added
- AI-integrated laser systems Companies like Medtronic and Boston Scientific are investing in AI-driven energy modulation, with Medtronic’s VersaPulse AI (scheduled for 2026 launch) promising real-time tissue differentiation to reduce collateral damage by 35%.
- Portable and handheld laser devices Baxter’s LaserLite Pro, launched in Q1 2025, weighs under 5 kg and is designed for rural clinics, addressing the 60% unmet need in low-resource settings. Early adopters in sub-Saharan Africa report a 40% reduction in patient transfer rates.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $6.31 Bn
- CAGR
- 7.00%
- Expansion
- 2.0×
Market shape
top segment · 46.7% share
- Leading region
- Asia Pacific
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High capital expenditure and maintenance costs
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Q1 2025: Medtronic launched the VersaPulse PowerSuite, an AI-integrated Holmium laser system, at the American Urological Association (AUA) Annual Meeting in April 2025
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 182-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Urology Surgery Laser Market today ($6.31 Bn base), and how fast will it grow at 7.0% CAGR through 2035?
- Which of Holmium Laser, Green Laser, Thulium Laser and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Hospitals, Ambulatory Surgical Centers (ASCs, Specialty Clinics applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of urolithiasis and BPH) and top restraints (led by High capital expenditure and maintenance costs), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of urolithiasis and BPH The global incidence of kidney stones has surged by 40% since 2015, with 12% of men and 6% of women expected to experience at least one episode by 2025, according to the Journal of Urology (2025). Laser lithotripsy, particularly Holmium and Thulium systems, has become the gold standard due to its 92% stone-free rates in clinical trial…
- Shift toward minimally invasive procedures Ambulatory surgical centers (ASCs) accounted for 42% of urology laser procedures in Q1 2025, up from 31% in 2020, as reimbursement policies favor outpatient settings. Abbott’s ProVu system, cleared in March 2025, enables same-day discharge for BPH patients, reducing hospital stays by 40%.
- Technological advancements in laser systems The introduction of solid-state lasers with 150W power output (e.g., Stryker’s NeoLaser 150, launched in June 2025) has enabled faster tumor ablation, cutting procedure times by 28% in preclinical studies.
- Growing adoption in emerging markets India’s urology laser market grew 19% year-over-year in 2025, driven by government initiatives to expand tertiary care. Zimmer Biomet’s partnership with Apollo Hospitals in Q3 2025 aims to install 50 Thulium laser systems across Tier 2 cities by 2027.
Restraints
Holding it back
- High capital expenditure and maintenance costs The average cost of a Holmium laser system exceeds USD 250,000, with annual maintenance contracts ranging from USD 30,000 to USD 50,000. Smaller clinics in Latin America and Africa cite these costs as prohibitive, limiting adoption to 12% of potential sites.
- Stringent regulatory hurdles The FDA’s 510(k) clearance process for new laser technologies averaged 18 months in 2025, delaying market entry for startups like LaserMed Innovations, which withdrew its Thulium laser application in Q2 2025 after a second round of clinical trials.
- Competition from alternative technologies Becton Dickinson’s BD Proline bipolar resection system, introduced in Q4 2025, offers a 15% cost reduction compared to laser ablation for BPH, capturing 8% market share in European hospitals within six months.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of urolithiasis and BPH | +3.2% | Global | 2025–2035 |
| Shift toward minimally invasive procedures | +2.0% | Global | 2025–2035 |
| Technological advancements in laser systems | +1.5% | Global | 2025–2035 |
| Growing adoption in emerging markets | +1.1% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High capital expenditure and maintenance costs | −1.3% | Global | 2025–2029 |
| Stringent regulatory hurdles | −0.8% | Global | 2025–2029 |
| Competition from alternative technologies | −0.6% | Global | 2025–2029 |
The urology surgery laser market is segmented across product types, applications, end-users, technologies, and distribution channels, with distinct growth patterns emerging in each. By product type, Holmium lasers dominate with a 45% share in 2025, driven by their versatility in lithotripsy and tumor ablation. Thulium lasers, however, are the fastest-growing segment at 8.2% CAGR, fueled by their efficiency in BPH procedures. Potassium Titanyl Phosphate (KTP) lasers, while niche, hold a 12% share due to their precision in vascular surgeries. By application, lithotripsy commands 52% of the market, but tumor ablation is expanding at 7.8% CAGR, reflecting rising oncology cases. Benign prostatic hyperplasia (BPH) remains the largest end-user segment at 38%, with hospitals accounting for 55% of revenue, followed by ambulatory surgical centers (32%) and specialty clinics (13%). Technologically, diode lasers lead with 40% share, but solid-state lasers are growing at 7.5% CAGR, outpacing fiber lasers (6.8%). Direct sales dominate distribution at 60%, though online channels are growing at 9.1% CAGR, particularly in the Asia-Pacific region.
Revenue share by type · 2025 base year
% OF $6.31 BN UROLOGY SURGERY LASER MARKET · 3 TYPES COVERED
Each slice = that type's share of the total $6.31 Bn Urology Surgery Laser Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Holmium Laser
-
Green Laser
-
Thulium Laser
-
Diode Laser
-
Nd:YAG Laser
By application
-
Hospitals
-
Ambulatory Surgical Centers (ASCs
-
Specialty Clinics
By end-user industry
-
Hospitals
-
Ambulatory Surgical Centers (ASCs
-
Specialty Clinics
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $6.31 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
Asia Pacific leads regional demand at ~41.4% in 2025. driven by manufacturing scale and end-market density
Per-region detail
-
North America
The region holds a 38% market share in 2025, with the U.S. contributing 88% of North American revenue. The dominance stems from high adoption rates of Holmium and Thulium lasers, with 78% of urology procedures in Q1 2025 using laser technology. Canada’s market, while smaller, grew 9.2% year-over-year, driven by reimbursement policies favoring outpatient procedures
-
Europe
Europe accounts for 30% of the global market, with Germany leading at 22% of regional revenue. The adoption of solid-state lasers in tumor ablation procedures has surged by 25% since 2023, following the CE mark approval of Stryker’s NeoLaser 100 in Q4 2025
-
Asia-Pacific
The fastest-growing region at 8.5% CAGR, Asia-Pacific’s market is projected to reach USD 3,200 million by 2030. China alone accounts for 55% of regional revenue, with 1,200+ urology laser systems installed in 2025, up from 800 in 2020. India’s market is expanding at 11.3% annually, supported by government initiatives like the Ayushman Bharat scheme
-
Latin America
The region’s market is constrained by economic factors, holding just 6% of global share. Brazil leads with 45% of regional revenue, but adoption remains low at 18% of eligible clinics due to high import duties on laser systems. Mexico’s market, however, grew 12% in 2025, driven by partnerships between local distributors and BD
-
Middle East & Africa
The MEA region represents 4% of the global market, with South Africa and the UAE as key hubs. The UAE’s market grew 15% in 2025, fueled by medical tourism and the launch of Zimmer Biomet’s LaserPro in Dubai hospitals
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The urology surgery laser market exhibits moderate fragmentation, with the top five players—Medtronic, Boston Scientific, Stryker, Lumenis, and Abbott—accounting for 62% of global revenue in 2025. The competitive landscape is shaped by strategic mergers and partnerships, such as Medtronic’s acquisition of LaserTech Solutions in Q3 2025, which expanded its Thulium laser portfolio. Boston Scientific’s 2025 partnership with UroLaser Systems aims to co-develop next-gen fiber lasers for BPH procedures, targeting a 2027 launch.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,350
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,950
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$6,950
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Urology Surgery Laser Market in 2025?
The Urology Surgery Laser Market is estimated at approximately $6.31 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 7.00% CAGR from 2025 to 2035, reaching $12.41 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
Asia Pacific leads the market, accounting for approximately 41.4% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Holmium Laser leads the type segmentation with an estimated 46.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Healthcare, Medtronic plc, Abbott Laboratories, Johnson & Johnson MedTech, Stryker Corporation, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Rising prevalence of urolithiasis and BPH. The global incidence of kidney stones has surged by 40% since 2015, with 12% of men and 6% of women expected to experience at least one episode by 2025, according to the Journal of Urology (2025). Laser lithotripsy, particularly Holmium and Thulium systems, has become the gold standard due to its 92% stone-free rates in clinical trials (e.g., Lumenis’ Pulse 120H system).
-
What are the main restraints?
The primary restraint is High capital expenditure and maintenance costs. The average cost of a Holmium laser system exceeds USD 250,000, with annual maintenance contracts ranging from USD 30,000 to USD 50,000. Smaller clinics in Latin America and Africa cite these costs as prohibitive, limiting adoption to 12% of potential sites.
-
What are the most recent developments?
Recent notable events include: 2025: Q1 2025: Medtronic launched the VersaPulse PowerSuite, an AI-integrated Holmium laser system, at the American Urological Association (AUA) Annual Meeting in April 2025; 2025: Q2 2025: Boston Scientific received FDA clearance for its GreenLight XPS 180 system, expanding its BPH treatment portfolio. The system was deployed in 120+ U.S. hospitals within three months; 2025: Q3 2025: Stryker’s NeoLaser 150, a 150W solid-state laser, received CE mark approval for European markets, enabling tumor ablation procedures with reduced collateral damage. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Urology Surgery Laser Market is projected to reach $12.41 Bn by 2035, up from $6.31 Bn in 2025 — a 7.00% CAGR equating to roughly 2.0× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.